Obesity pharmacotherapy: drugs available in Brazil and effectiveness and safety profiles





Pharmacological treatment; Obesity; Anti-obesity drugs.


The pharmacological treatment of obesity is constantly updated and the development of new products and proposals is often seen as a controversial option that requires a careful evaluation for its use, both with regard to the patient's clinical condition and the general characteristics of the drug. to be used, making it necessary to know about its action and safety profiles related to its use. The objective is identify and systematize the most recent data present in the literature on the main drugs used in the treatment of obesity in Brazil and their adverse reactions. Integrative review of articles published in Portuguese, English and Spanish, available in full on LILACS, BIREME (BVS) and MedLine databases. The keywords "drug therapy" AND "obesity" were used for the LILACS database, "pharmacological therapy" AND "obesity" for the Medline / Pubmed database and "drugs" AND "anti-obesity" for the BIREME / VHL database for articles published in the period from 2015 to 2020, 15 studies were selected and analyzed. Results: in LILACs, MEDLINE / PUBMED and BIREME / VHL databases, 16, 49 and 305 articles were obtained, respectively, as results. At the end of all analyzes and selection criteria, 15 articles were included in the present study. Most of the drugs approved for the pharmacotherapy of obesity in Brazil have demonstrated in clinical trials well-established efficacy in weight loss. Similar rates of adverse events were observed between orlistat, liraglutide and lorcaserin, with liraglutide having the largest gastrointestinal events in the group. In the study carried out, the possibilities of new pharmacological treatments for obesity that showed greater strength in the results of weight loss, were exenatide and melatonin, with efficacy demonstrated in clinical trials.

Author Biographies

Kevellyn Bezerra Utta, Universidade Federal do Maranhão

Médica, graduada pela Universidade Federal do Maranhão, CCHNST. 

Débora Luana Ribeiro Pessoa, Universidade Federal do Maranhão

Coordenação do curso de Medicina

Campus Pinheiro

Universidade Federal do Maranhão


Agência Nacional de Saúde Suplementar (2017). Manual de diretrizes para o enfretamento da obesidade na saúde suplementar brasileira. Rio de Janeiro.

Amstrup, A. K., Sikjaer, T., Pedersen, S. B., Heickendorff, L., Mosekilde, L., & Rejnmark, L. (2016). Reduced fat mass and increased lean mass in response to 1 year of melatonin treatment in postmenopausal women: A randomized placebo‐controlled trial. Clinical Endocrinology, 84(3), 342-347.

Anvisa, Associação Nacional de Vigilância Sanitária. (2017). Dispõe sobre a comercialização e manipulação dos anorexígenos sibutramina, anfepramona, femproporex e mazindol.

Ard, J., Cannon, A., Lewis, C. E., Lofton, H., Vang Skjøth, T., Stevenin, B., & Pi‐Sunyer, X. (2016). Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials. Diabetes, Obesity nd Metabolism, 18(4), 430-435.

Arzola‐Paniagua, M. A., García‐Salgado López, E. R., Calvo‐Vargas, C. G., & Guevara‐Cruz, M. (2016). Efficacy of an orlistat‐resveratrol combination for weight loss in subjects with obesity: A randomized controlled trial. Obesity, 24(7), 1454-1463.

Costa, A. M. J, & Duarte, S. F. P. (2017). Principais medicamentos utilizados no tratamento da obesidade e vias de ação: uma revisão sistemática. Id On Line Revista de Psicologia, 11(35), 199-209.

Davies, M. J., Aronne, L. J., Caterson, I. D., Thomsen, A. B., Jacobsen, P. B., Marso, S. P., & Satiety and Clinical Adiposity–Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups. (2018). Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials. Diabetes, Obesity and Metabolism, 20(3), 734-739.

Gadde, K. M., Apolzan, J.W., Berthoud, H. R. (2018). pharmacotherapy for patients with obesity. Clinical chemistry, v. 64, n. 1, p. 118-129.

Grabarczyk, T. R. (2018). Observational comparative effectiveness of pharmaceutical treatments for obesity within the veterans health administration. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 38(1), 19-28.

Hurren, K. M., & Dunham, M. W. (2017). Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity. Expert opinion on drug metabolism & toxicology, 13(8), 891-896.

Instituto Brasileiro de Geografia e Estatística (IBGE). Pesquisa Nacional de Saúde 2019. Prevalência da obesidade entre adultos no Brasil. [Internet]. Rio de Janeiro: Instituto Brasileiro de Geografia e Estatística; 2020. Disponível em: https://biblioteca.ibge.gov.br/index.php/bibliotecacatalogo?view=detalhes&id=2101764. Acesso em: 15 fev. 2021.

Isaacs, D., Prasad-Reddy, L., & Srivastava, S. B. (2016). Role of glucagon-like peptide 1 receptor agonists in management of obesity. American journal of health-system pharmacy, 73(19), 1493-1507.

Lucchetta, R. C., Riveros, B. S., Pontarolo, R., Radominski, R. B., Otuki, M. F., Fernandez-Llimos, F., & Correr, C. J. (2017). Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients. Clinics, 72(5), 317-324.

Nuffer, W., Trujillo, J. M., & Megyeri, J. (2016). A comparison of new pharmacological agents for the treatment of obesity. Annals of Pharmacotherapy, 50(5), 376-388.

O'Neil, P. M., Aroda, V. R., Astrup, A., Kushner, R., Lau, D. C., Wadden, T. A., ... & Satiety and Clinical Adiposity–Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups. (2017). Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials. Diabetes, Obesity and Metabolism, 19(11), 1529-1536.

Pereira A. S. et al. (2018). Metodologia da pesquisa científica. [free e-book]. Santa Maria/RS. Ed. UAB/NTE/UFSM.

Radaelli, M., Pedroso, R. C., & Medeiros, L. F. (2016). Farmacoterapia da obesidade: Benefícios e Riscos. Saúde e Desenvolvimento Humano, 4(1), 101-115.

Shettar, V., Patel, S., & Kidambi, S. (2017). Epidemiology of obesity and pharmacologic treatment options. Nutrition in Clinical Practice, 32(4), 441-462.

Silva, F. I. L., Rodrigues, G., Bonelli, O. A. (2019). O risco do uso dos anorexígenos disponíveis no brasil para o tratamento da obesidade. Revista saberes, 9(1).

Sociedade Brasileira de Endocrinologia e Metabologia (2010). Obesidade e sobrepeso: tratamento farmacológico. Brasília: Associação Médica Brasileira e Conselho Federal de Medicina.

Wadden, T. A., Tronieri, J. S., Sugimoto, D., Lund, M. T., Auerbach, P., Jensen, C., & Rubino, D. (2020). Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial. Obesity, 28(3), 529-536.

Weghuber, D., Forslund, A., Ahlström, H., Alderborn, A., Bergström, K., Brunner, S., ... & Bergsten, P. (2020). A 6‐month randomized, double‐blind, placebo‐controlled trial of weekly exenatide in adolescents with obesity. Pediatric obesity, 15(7), e12624.



How to Cite

UTTA, K. B. .; PESSOA, D. L. R. Obesity pharmacotherapy: drugs available in Brazil and effectiveness and safety profiles. Research, Society and Development, [S. l.], v. 10, n. 12, p. e218101218829, 2021. DOI: 10.33448/rsd-v10i12.18829. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/18829. Acesso em: 20 feb. 2024.



Health Sciences